Dainius Balis

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

William T. Cefalu, Lawrence A. Leiter, Kun‐Ho Yoon et al. · The Lancet · 2013 · 718 citations

Metabolic Syndrome, Diabetes Management, Canagliflozin Versus Glimepiride +8

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

Hiddo J.L. Heerspink, Mehul Desai, Meg Jardine et al. · Journal of the American Society of Nephrology · 2016 · 336 citations · Full text

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Lawrence A. Leiter, Kun‐Ho Yoon, Pablo Arias et al. · Diabetes Care · 2014 · 221 citations · Full text

A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation

Susan Nicholson, Tobias Welte, Thomas M. File et al. · International Journal of Antimicrobial Agents · 2012 · 150 citations

Community-acquired Pneumonia, Ceftobiprole Medocaril, Antimicrobial Stewardship +7

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

Lawrence A. Leiter, Thomas Först, David Polidori et al. · Diabetes & Metabolism · 2015 · 125 citations

Metabolic Syndrome, Diabetes Management, Hepatology +11